MedTrace Logo

Tislelizumab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With Advanced CRC

NCT04924179 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2022-08-17

No results posted yet for this study

Summary

A Phase II Study to Assess the Efficacy and Safety of Tislelizumab Combined With Fruquintinib and SBRT as A third-line and Posterior Line Treatment in Patients With Advanced Colorectal Cancer

Conditions

  • Patients With Advanced Metastatic Colorectal Cancer

Interventions

DRUG

Tislelizumab plus Fruquintinib and SBRT

Fruquintinib:5mg ,qd,po, d1-d14, 21 days for a cycle;Tislelizumab Injection:200mg，IV,d1,21 days for a cycle;SBRT:8-10Gy×5F,qod,in 10 days.

Sponsors & Collaborators

  • Huazhong University of Science and Technology

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-01
Primary Completion
2022-12-31
Completion
2024-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04924179 on ClinicalTrials.gov